Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment

被引:1
|
作者
Knott, Tanya [1 ,2 ]
Creeden, James [2 ,3 ,4 ]
Horbach, Benjamin [2 ,3 ,5 ]
Rauch-Zumbragel, Maximiliane [2 ,3 ,7 ]
Vat, Lidewij [2 ,3 ]
Harnik, Helena [2 ,3 ]
Maravic, Zorana [2 ,3 ,6 ]
机构
[1] Sarah Jennifer Knott Fdn, Dublin, Ireland
[2] From Testing Targeted Treatments FT3, Brussels, Belgium
[3] The Synergist, Brussels, Belgium
[4] Creeden Consulting, Basel, Switzerland
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Digest Canc Europe, Brussels, Belgium
[7] The Synergist, From Testingto Targeted Treatments FT3 Program Tea, Ave Louise 231, B-1050 Brussels, Belgium
关键词
equitable access; patient advocacy; precision medicine; priorities; stakeholder alignment; stakeholder expectations; PERSONALIZED MEDICINE; RECOMMENDATIONS; ACCESS; HEALTH;
D O I
10.1002/hsr2.1428
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and AimsTo sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the expectations of different stakeholders from themselves and each other regarding PM. MethodsThis collaborative qualitative study was initiated by the global multistakeholder consortium From Testing to Targeted Treatments (FT3). Structured interviews were conducted with participants from five stakeholder groups: patients/patient advocates, healthcare providers (HCPs), researchers, policymakers/regulators/payers and industry representatives. A broad reach across geography, roles, experiences, and disease areas was sought. Results were analyzed by grounded theory methodology. ResultsAll stakeholders stated that optimal implementation of PM can only be achieved through collaboration; industry representatives were the biggest promoters of collaboration. Stakeholders agreed that PM should be implemented focusing on the patient's best interest; HCPs were seen as important gatekeepers for PM by interacting directly with patients, and policymakers/payers were perceived as the most important drivers of access to PM. Areas of misalignment included the role of industry in clinical trial design and in access to PM (perceived as important by patients, HCPs and policymakers but not by industry representatives), and the stakeholders responsible for elaborating guidelines on PM use (patients indicated policymakers, while researchers indicated themselves). Priorities for optimal PM implementation and suggested actions included the need for enhancing high-level policy focus, improving genomic literacy, optimizing the health technology assessment for PM, advocating for equitable access, promoting collaboration between industry and other stakeholder groups and development of reliable research standards. ConclusionStakeholder expectations revealed in this study suggested that no stakeholder group can drive change on its own; a global, multistakeholder collaborative approach that brings together current programs and best practices to support universal access to PM is needed.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Expectations Regarding Workplace Health Coaching A Qualitative Study With Stakeholders
    Dejonghe, Lea A. L.
    Biallas, Bianca
    McKee, Lorna
    Rudolf, Kevin
    Froboese, Ingo
    Schaller, Andrea
    [J]. WORKPLACE HEALTH & SAFETY, 2019, 67 (07) : 317 - 325
  • [2] A qualitative study exploring caregivers' experiences, perspectives, and expectations for precision medicine in epilepsy in South Africa
    Muchada, Irene Farisai
    Wilmshurst, Jo M.
    Laing, Nakita
    Davies, Elin Haf
    Fieggen, Karen
    [J]. EPILEPSY & BEHAVIOR, 2021, 117
  • [3] Ethical issues in oncology practice: a qualitative study of stakeholders' experiences and expectations
    Crico, Chiara
    Sanchini, Virginia
    Casali, Paolo G.
    Pravettoni, Gabriella
    [J]. BMC MEDICAL ETHICS, 2022, 23 (01)
  • [4] Ethical issues in oncology practice: a qualitative study of stakeholders’ experiences and expectations
    Chiara Crico
    Virginia Sanchini
    Paolo G. Casali
    Gabriella Pravettoni
    [J]. BMC Medical Ethics, 23
  • [5] 145 ASSESSING MEDICINE LISTS: A QUALITATIVE STUDY WITH MULTIPLE STAKEHOLDERS
    O'Donovan, B.
    Kirke, C.
    Pate, M.
    McHugh, S.
    Bennett, K.
    Cahir, C.
    [J]. AGE AND AGEING, 2022, 51 (SUPP 3)
  • [6] Professional stakeholders' expectations for the future of community pharmacy practice in England: a qualitative study
    Paloumpi, Evgenia
    Ozieranski, Piotr
    Watson, Margaret C.
    Jones, Matthew D.
    [J]. BMJ OPEN, 2023, 13 (10):
  • [7] External stakeholders' expectations and experiences regarding the Portuguese Hospital Centres - a qualitative study results
    Simoes, Ana
    Azevedo, Americo
    Goncalves, Suzete
    [J]. INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2014, 14
  • [8] The Voices of Stakeholders Involved in Precision Medicine: The Co-Design and Evaluation of Qualitative Indicators of Intervention Acceptability, Fidelity and Context in PRecISion Medicine for Children With Cancer in Australia
    Smith, James
    Braithwaite, Jeffrey
    O'Brien, Tracey A.
    Smith, Stephanie
    Tyrrell, Vanessa J.
    Mould, Emily V. A.
    Long, Janet C.
    Rapport, Frances
    [J]. QUALITATIVE HEALTH RESEARCH, 2022, 32 (12) : 1865 - 1880
  • [9] Stakeholders' expectations and perceived effects of the pharmacy ownership liberalization reform in Sweden: a qualitative interview study
    Wisell, Kristin
    Winblad, Ulrika
    Sporrong, Sofia Kalvemark
    [J]. BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [10] Stakeholders’ expectations and perceived effects of the pharmacy ownership liberalization reform in Sweden: a qualitative interview study
    Kristin Wisell
    Ulrika Winblad
    Sofia Kälvemark Sporrong
    [J]. BMC Health Services Research, 16